Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

Literature DB >> 30837213

Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

Victoria A Chang¹, Huan-You Wang², Erin G Reid³.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2019 PMID： 30837213 PMCID： PMC6418491 DOI： 10.1182/bloodadvances.2018026351

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

× No keyword cloud information.

12 in total

Review 1. Current status of treatment for primary effusion lymphoma.

Authors: Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal: Intractable Rare Dis Res Date: 2014-08

2. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors: R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal: Blood Date: 1996-07-15 Impact factor: 22.113

3. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.

Authors: Emmanuelle Boulanger; Laurence Gérard; Jean Gabarre; Jean-Michel Molina; Christophe Rapp; Jean-François Abino; Jacques Cadranel; Sylvie Chevret; Eric Oksenhendler
Journal: J Clin Oncol Date: 2005-07-01 Impact factor: 44.544

Review 4. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors: Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079

5. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors: Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245

6. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors: Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal: Blood Date: 2013-07-09 Impact factor: 22.113

7. Update on HHV-8-Associated Malignancies.

Authors: Meena Sunil; Erin Reid; Mary Jo Lechowicz
Journal: Curr Infect Dis Rep Date: 2010-03-26 Impact factor: 3.725

8. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution.

Authors: Stéphanie Guillet; Laurence Gérard; Véronique Meignin; Felix Agbalika; Wendy Cuccini; Blandine Denis; Christine Katlama; Lionel Galicier; Eric Oksenhendler
Journal: Am J Hematol Date: 2016-02 Impact factor: 10.047

9. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.

Authors: Cecelia Simonelli; Michele Spina; Roberta Cinelli; Renato Talamini; Rosamaria Tedeschi; Annunziata Gloghini; Emanuela Vaccher; Antonio Carbone; Umberto Tirelli
Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544

10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors: Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal: Lancet Date: 2018-12-04 Impact factor: 79.321

5 in total

Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma.

Review 1. Current status of treatment for primary effusion lymphoma.

2. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

3. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.

Review 4. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

5. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

6. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

7. Update on HHV-8-Associated Malignancies.

8. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution.

9. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.

10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Review 1. Immunotherapy for KSHV-associated diseases.

2. Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma.

Review 3. KSHV/HHV8-mediated hematologic diseases.

4. [Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].

5. T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver Cirrhosis.